EndoStim receives FDA breakthrough device designation for the EndoStim system for the treatment of drug refractory GERD

EndoStim

25 October 2022 - EndoStim announced today that the US FDA granted breakthrough device designation for the Company’s EndoStim system.

The EndoStim system consists of an implantable neurostimulation device and lead placed via a quick, minimally invasive laparoscopic procedure.

Read EndoStim press release

Michael Wonder

Posted by:

Michael Wonder